Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Water Tower Research Publishes Report on Omniscient Neurotechnology Pty Limited, “Making Brain Data Actionable at Scale; Revolutionizing Brain Health”August 25, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published a report on Omniscient Neurotechnology Pty Limited titled, “Making Brain Data Actionable at Scale; Revolutionizing Brain Health”. The report can be accessed here. Omniscient Neurotechnology Pty Limited […]
- The Landes GroupTHE LANDES GROUP COMPLETES ACQUISITION OF ENCORE MEDICAL CENTER, FINALIZES LONG-TERM LEASE WITH UAMSOwnership structure enables UAMS to expand while preserving institutional capital — The Landes Group, a Dallas-based real estate investment firm specializing in healthcare real estate and capital solutions, today announced it has completed the...
- Nihon KohdenNihon Kohden Expands Executive Leadership to Support Continued Growth and Customer ExperienceIRVINE, Calif., August 25, 2026--Nihon Kohden, a leading provider of patient monitoring, neurology, ventilation and digital health solutions, today announced an expanded executive leadership structure designed to increase organizational capacity and strengthen alignment across the customer experience. Effective August 3, Zac Ballard was promoted to executive vice president, commercial operations, taking on leadership of sales and marketing across all four of the company’s business units — Patien
- OneLegacy Celebrates the Career and Contributions of Medical Director Dr. Gabriel Danovitch, the 2026 Recipient of the Medawar PrizeAZUSA, Calif., August 25, 2026--OneLegacy, the nonprofit organ, eye, and tissue procurement organization serving seven counties across Southern California, celebrates the extraordinary career and contributions of Dr. Gabriel Danovitch, who is retiring from his role as Medical Director after over two decades with OneLegacy, while simultaneously receiving one of the most prestigious honors of his career: The Transplantation Society’s 2026 Medawar Prize.
- China State Construction International Empowers Market Expansion through TechnologyChina State Construction International Holdings Limited (“China State Construction International” or the “Group”, stock code: 03311) has announced its 2026 interim results, recording net profit of RMB4,330 million for the first half of the year and a dividend payout ratio of 35.4%. Notably, the Group’s cash flow performance was particularly strong, with net operating cash flow reaching RMB3,796 million in the first half, while its cash-to-net-profit ratio stood at 87.7%, a near 15-year high. Across its business segments, the Group achieved robust growth, with its MiC (Modular Integrated Construction) business successfully securing a number of landmark projects, reflecting the strategic outcome of the Group’s steadfast efforts over the years to transform its business from traditional on-site construction towards new industrialised construction. Technology empowerment has evolved from a standalone technical advantage into a core competitive strength and a key driver of the Group’s long-term value creation. As one of the earliest companies in the Chinese Mainland to embrace construction industrialisation, the Group has reshaped the traditional construction model through its self-developed “Smart Construction – MiC technology”. By shifting from the construction site to the factory, and converting sequential processes into parallel workflows, the Group has effectively shortened construction periods, strengthened cost control, and reduced reliance on on-site labour and weather conditions. This transformation has become a core foundation for the Group to navigate industry cycles and drive improvement in its operating performance. Hong Kong: Serving Community Needs through MiC, with Landmark Projects Progressing One after Another China State Construction International’s technological practices are closely aligned with the policy direction of the Hong Kong SAR Government. Since 2017, MiC has been included in the Policy Address for eight consecutive years, while the Government has promoted new construction methods through measures such as gross floor area and building height concessions, as well as the Construction Innovation and Technology Fund. These initiatives have provided the Group with clear policy support and market opportunities. During the period, the Group secured a number of landmark projects, including the Kwu Tung North Joint User Complex, the first government facilities cluster in the Northern Metropolis, and the University of Macau campus project in the Hengqin Guangdong-Macao Intensive Cooperation Zone (North District). The Group’s Temple Street project has also topped out successfully. As Hong Kong’s first full-MiC private residential project, it achieved a pace of “one floor every three days” despite stringent road traffic restrictions. The Kai Tak Light Public Housing project, Hong Kong’s largest light public housing development, was delivered ahead of schedule, with 70% of the construction processes completed in factories in the Greater Bay Area. It achieved the installation of one module every 30 minutes and the completion of one floor every three days, substantially shortening waiting time and demonstrating the strategic positioning of “what Hong Kong needs, what the Group excels at”. The project also received a Completion Commendation Letter from the Architectural Services Department. The strategic value of the Group’s technology was demonstrated as early as during the pandemic. In 2020, the Group completed the North Lantau Hospital Hong Kong Infection Control Centre, the world’s first infectious disease hospital with full-MiC negative-pressure isolation wards, in just four months. This showcased the application value of MiC in major public emergencies, deepened recognition from the Government and the market of the Group’s construction capabilities and emergency-response capacity, and laid a strong reputational foundation for undertaking large-scale public infrastructure projects. Looking ahead, the Northern Metropolis is expected to become a new growth engine for the Group. The latest Budget proposed the first transfer of HK$150 billion in investment returns from the Exchange Fund to support infrastructure including the Northern Metropolis, while annual capital works expenditure is expected to increase from approximately HK$90 billion to around HK$120 billion over the next five years. Covering site formation, transport, public facilities and public housing, the Northern Metropolis is expected to involve total investment of more than HK$3 trillion, presenting considerable development potential. MiC modular construction can shorten construction periods by approximately 70%, aligning well with the Northern Metropolis’ need for rapid development. Together with Budget support for the direct procurement of Modular Integrated Construction units, this is expected to further unlock market demand. The Group has established 12 smart housing manufacturing bases nationwide and assembled a team of more than 300 design and R&D professionals, giving it advantages in scaled technology and production capacity. According to forecasts by the Development Bureau and the Construction Industry Council, the total MiC floor area in Hong Kong is expected to reach approximately 2.5 million square metres between 2025 and 2030, indicating substantial market opportunities. Chinese Mainland: Urban Renewal Opens a New Growth Driver as MiC Expands across Multiple Cities In May 2026, the State Council issued the 15th Five-Year Plan for Urban Renewal, the first national-level special plan for China’s urban renewal sector. Market estimates that urban renewal could drive investment of RMB15 trillion to RMB20 trillion during the period. Leveraging its MiC technology, the Group has developed benchmark redevelopment projects such as Huapichang Hutong in Beijing and Tianlin Road in Xuhui, Shanghai, achieving first-mover presence in first-tier cities. Going forward, the Group will replicate and scale mature models through its full-chain capabilities in “operation + technology + investment + construction”, positioning urban renewal as a core growth driver for its Chinese Mainland business. During the period, the Group’s newly signed MiC contracts in the Chinese Mainland increased by more than 70%, with progress across multiple first-tier cities and orderly expansion into strong second-tier cities. In Beijing, the Group has secured four rapid classroom construction projects in Fengtai District. In Guangzhou, the Group won its first MiC resettlement housing project in Conghua District. In Shanghai and Suzhou, the country’s largest concrete MiC urban renewal project — the demolition and reconstruction of old housing at Lane 65, Tianlin Road, Xuhui District — was officially delivered and well received by various stakeholders. The Group successively secured Shanghai’s second and Hongkou District’s first MiC in-situ redevelopment projects, and successfully won Suzhou’s first MiC project under an “investment + technology” model, further deepening its market presence. The positive results of the Group’s MiC modular transformation are becoming increasingly evident. Looking ahead, the Group will continue to seize the structural opportunities presented by Hong Kong’s Northern Metropolis and the urban renewal market in the Chinese Mainland, further harness technology, reinforce its industry leadership, pursue high-quality growth and create sustainable, long-term value for shareholders.
- Neurologists Interested in Cell Therapy in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption, According to Spherix Global InsightsNew research finds neurologists anticipate meaningful durable remission in neuro-immune disease, while long-term safety, patient selection, and treatment logistics remain central to future uptake.
- AI Is Reshaping Clinical Nutrition: Precision Therapy, Venture Capital, and the Food-as-Medicine Frontier“AI is turning clinical nutrition into a more personalized, adaptive and data-driven component of patient care.”
- Allsup Explains What Workers With Chronic Pain Should Know About SSDI In 2026Understanding how the Social Security Administration evaluates pain, medical evidence and work limitations can help applicants build a stronger disability claim
- TranscarentTranscarent Launches Innovative Bundled Payment Model for Breakthrough Cancer TherapiesSAN FRANCISCO, August 25, 2026--Transcarent, the first agentic AI-powered health and care platform, today announced a first-of-its-kind bundled payment model for bispecific T-cell engager (BiTE) and CAR T therapies delivered through high-quality community providers, further enhancing their industry-leading complex care Centers of Excellence (COE) capabilities. The model enables Transcarent’s Cancer Care experience to bring advanced cancer care closer to where Members live while giving employers
- BeOne Medicines Ltd.BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEASAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction,
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaZymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).
- Covation Sponsors Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong CyclothonCovation Holdings Limited (“Covation” or the “Group”), a world-leading wheeled product innovator and manufacturer, is pleased to announce its sponsorship of the Covation Family Fun Ride at the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. Organized by the Hong Kong Tourism Board (“HKTB”), the flagship international sporting spectacle will take place on 11 October (Sunday), bringing together thousands of cyclists across the city’s iconic bridges and landmarks while showcasing the unique scenery. Mr. Bruno Maier, Co-CEO of Covation, said, “We are proud to support the Hong Kong Cyclothon—a world-class sporting spectacle that showcases the energy and iconic landscape of Hong Kong. As a global force in outdoor adventure, Covation shares the event’s passion for driving health, wellness, and a vibrant cycling culture across the community, as well as its sports for charity spirit. While the Cyclothon brings together elite global competitors and cycling enthusiasts, our sponsorship of the Family Fun Ride allows us to introduce families and young riders to the transformative joy of cycling. Through our century-old children’s bicycle brand, Huffy, we have inspired generations to connect through cycling. We are thrilled to play a meaningful role in this citywide extravaganza, offering families a unique opportunity to create lasting memories together while supporting a charitable cause.” Covation – a name that merges “Collaboration” and “Innovation” — is on a mission to revolutionize how people move, connect, and explore—by developing exceptional products for bold experiences across wheeled categories and beyond. It is a Hong Kong-headquartered vertically integrated holding company, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, driven by manufacturing excellence. The Group owns multiple outdoor cycling brands, including Huffy, Batch, and Green Machine. Currently, its business serves millions of consumers across more than 50 countries and regions worldwide. The Covation Family Fun Ride is designed to encourage outdoor recreation and family bonding. Open to participants aged 6 to 70, each entry group consists of one parent paired with one child or youth. In line with the Cyclothon’s sports for charity spirit, registration fees collected from the Covation Family Fun Ride will be donated in full to The Community Chest of Hong Kong to support local underprivileged communities. Beyond the rides, the event will host a dedicated cycling-themed carnival at the West Kowloon Cultural District, featuring a diverse programme of sports, entertainment, family-friendly activities and culinary delights, allowing locals and visitors to fully immerse themselves in the excitement of the cycling extravaganza. Covation will also host a booth at the venue, featuring its exceptional wheeled products and connecting with cycling enthusiasts. This year’s Cyclothon is further enriched new elements, including an upgraded 56km non-competitive ride on a “Five Tunnels, Three Bridges” route that will take riders along roads rarely opened to cyclists. The enhanced route provides an ideal opportunity to explore Hong Kong’s diverse urban landscapes, showcasing the unique blend of old and new districts. This, together with the 32km ride, is expected to see the participation of more than 6,500 cyclists. Covation Family Fun Ride Highlights: Event Date: Sunday, 11 October 2026 Group Format: 1 Parent + 1 Child/Youth (6–70 years old) Entry Fee: HK$100 per group (100% donated to charity) Public Registration: Registration is now open via the event website Photo: Bruno Maier (row 2, 3rd from right), Covation Co-CEO, joins Hong Kong Tourism Board officials and event partners at the launch press conference of the 2026 Sun Hung Kai Properties Hong Kong Cyclothon. About Covation Holdings Limited Covation Holdings Limited (“Covation”) is a vertically integrated holding company headquartered in Hong Kong, specializing in the research, development, manufacturing, distribution and global operations of cycling and outdoor brands, as well as excellence in manufacturing. As a world-leading manufacturer and assembler of bicycles and components, the company operates modern smart manufacturing facilities in China, Cambodia and Vietnam. Leveraging its vertically integrated supply chain advantages and rigorous quality control system, Covation has established an efficient operational network with strategic branches across the United States, Mexico, Canada, the United Kingdom, European Union, Hong Kong, and China, consistently delivering exceptional products to global customers. Covation’s portfolio encompasses internationally renowned outdoor sports brands, including Huffy, Batch, and Green Machine. The company maintains extensive licensing partnerships with world-class partners such as Disney, Marvel, Lucasfilm, Universal Studios, Paramount, Microsoft, and Sanrio.